title: Stimulation of nitric oxide synthesis and protective role of insulin in acute thrombosis in vivo.
abstract: Administration of physiologic amounts of insulin in mice (200 microunits/g body weight) resulted in 9 fold increase of basal nitric oxide level from 0.51+/-0.1224 nmol/ml (mean+/-SD, n=12) to 4.45+/-0.645 nmol/ml after 30min of the injection of the hormone. Since NO is a potent inhibitor of platelet aggregation both in vitro and in vivo, we tested the possibility whether the administration of the hormone would result in the in vivo inhibition of thrombosis through the increase of NO level in the circulation. It was found that administration of insulin (200 microunits/g body weight) in mice protected >90%(p<0.00001, n=500) of these animals from death due to thrombosis in the coronary arteries induced by ADP injection in the heart. This effect of insulin in vivo was found to be directly related to the hormone induced increase of NO level in the system. The thromboprotective effect of insulin could not be achieved by using either prostacyclin, a well known antithrombotic agent or its stable probe prostaglandin E1 instead of insulin. The efficacy of insulin was neither related to the blood glucose level nor was the consequence of the hypoglycemic effect of the hormone. In contrast, inhibition of insulin induced increase of NO level resulted in the complete loss of the thromboprotective effect of the hormone. These results suggest that insulin besides being a hypoglycemic hormone could also be a potent antithrombotic humoral factor.
authors.affiliation: Department of Life Science and Biotechnology, Jadavpur University, Calcutta-32, India.
authors.forename: A K
authors.initials: AK
authors.lastname: Sinha
authors.forename: S
authors.initials: S
authors.lastname: Bhattacharya
authors.forename: K
authors.initials: K
authors.lastname: Acharya
authors.forename: S
authors.initials: S
authors.lastname: Mazumder
mesh_terms: D000244:Adenosine Diphosphate / Q000008:administration & dosage; D000527:Alprostadil / Q000494:pharmacology; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D003327:Coronary Disease / Q000139:chemically induced / Q000517:prevention & control; D004791:Enzyme Inhibitors / Q000494:pharmacology; D011464:Epoprostenol / Q000494:pharmacology; D005260:Female; D007328:Insulin / Q000008:administration & dosage / Q000494:pharmacology*; D007700:Kinetics; D008297:Male; D051379:Mice; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D009569:Nitric Oxide / Q000096:biosynthesis* / Q000097:blood; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D013927:Thrombosis / Q000517:prevention & control*
chemical_list: D001786:Blood Glucose; D004791:Enzyme Inhibitors; D007328:Insulin; D009569:Nitric Oxide; D000244:Adenosine Diphosphate; D011464:Epoprostenol; D019001:Nitric Oxide Synthase; D000527:Alprostadil; D019331:NG-Nitroarginine Methyl Ester